home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

Overcome Targeted Alpha Therapy Challenges for Clinical Translation

 
  October 14, 2026  
     
 


Xtalks — The Life Science Community™, Online webinar
2026-12-11


Targeted alpha therapies are emerging as a promising area of radiopharmaceutical development, delivering high-potency, short-range radiation designed to target cancer cells while limiting damage to surrounding healthy tissue. As pipelines expand beyond beta-emitting therapies, radionuclides including actinium-225 (Ac-225), lead-212 (Pb-212) and astatine-211 (At-211) are attracting growing interest. This webinar explores the scientific and technical considerations shaping the development and clinical translation of targeted alpha therapy.

Despite their therapeutic potential, advancing targeted alpha therapies toward clinical applications requires overcoming several scientific and technical challenges that can influence overall development success. Key considerations include vector selection, radiochemistry, chelation and stability, as well as the complexities of dosimetry, biodistribution and toxicity. Additionally, daughter radionuclide redistribution, isotope availability and production scalability introduce further challenges that can affect therapeutic safety, efficacy and clinical readiness.

The featured speaker will explore the evolving targeted alpha therapy landscape, from key radionuclides and radiochemistry strategies to dosimetry, toxicity, isotope supply and translation. Attendees will gain a practical perspective on the scientific challenges that must be addressed to advance alpha-emitting radiopharmaceuticals toward the clinic.

Register for this webinar to learn about the key challenges in targeted alpha therapy development and the considerations necessary to support successful clinical translation.

 
 
Organized by: Xtalks — The Life Science Community™
Invited Speakers:

Julian Goggi, PhD, Perceptive Discovery

 
Deadline for Abstracts: 2026-12-11
 
Registration:

https://xtalks.com/webinars/overcome-targeted-alpha-therapy-challenges-for-clinical-translation/

E-mail: clientservices@xtalks.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2026 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.